| Title: | Do double-expressor high-grade B-cell lymphomas really need intensified treatment : a report from the real-life series of high-grade B-cell lymphomas treated with different therapeutic protocols at the Institute of Oncology Ljubljana |
|---|
| Authors: | ID Boltežar, Lučka (Author)
ID Rožman, Samo (Author)
ID Gašljević, Gorana (Author)
ID Grčar-Kuzmanov, Biljana (Author)
ID Jezeršek Novaković, Barbara (Author) |
|---|
| Files: |  URL - Source URL, visit https://www.mdpi.com/2227-9059/12/2/275
 PDF - Presentation file, download (1004,13 KB)
MD5: 0B65236A0D9289CF428EF4900DDF9FCC
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed. Only patients with double-expressor lymphoma (DEL), double-hit lymphoma (DHL), or triple-hit lymphoma (THL) were included. Demographic and clinical parameters were assessed, as well as progression-free survival (PFS) and overall survival (OS). In total, 161 cases out of 309 (161/309; 52,1%) were classified as DEL. Sixteen patients had DHL, MYC/BCL2 rearrangement was observed in eleven patients, and MYC/BCL6 rearrangement was observed in five patients. Five patients were diagnosed with THL. Out of 154 patients (according to inclusion/exclusion criteria) included in further evaluation, one-hundred and thirty-five patients had double-expressor lymphoma (DEL), sixteen patients had DHL, and three patients had THL. In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The median follow-up was 22 months. The 5-year OS for the whole DEL group was 57.1% (95% CI 45.9–68.3%) and the 5-year PFS was 76.5% (95% CI 72.6–80.4%). The log-rank test disclosed no differences in survival between treatment groups (p = 0.712) while the high-risk international prognostic index (IPI) carried a significantly higher risk of death (HR 7.68, 95% CI 2.32–25.49, p = 0.001). The 5-year OS for DHL patients was 32.4% (95% CI 16.6–48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients. |
|---|
| Keywords: | lymphoma, double-expressor lymphoma, oncology |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Submitted for review: | 25.12.2023 |
|---|
| Article acceptance date: | 22.01.2024 |
|---|
| Publication date: | 25.01.2024 |
|---|
| Publisher: | MDPI |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 275-1-275-13 |
|---|
| Numbering: | Vol. 12, no. 2 |
|---|
| Source: | Basel, Switzerland |
|---|
| PID: | 20.500.12556/DiRROS-18737  |
|---|
| UDC: | 616.4 |
|---|
| ISSN on article: | 2227-9059 |
|---|
| DOI: | 10.3390/biomedicines12020275 |
|---|
| COBISS.SI-ID: | 183791619 |
|---|
| Copyright: | by Authors |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 5. 2. 2024;
|
|---|
| Publication date in DiRROS: | 18.04.2024 |
|---|
| Views: | 69 |
|---|
| Downloads: | 24 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
